Plasma thrombin activatable fibrinolysis inhibitor levels in Behcet's disease

ÖZCAN M. A., Akar S., ALACACIOĞLU İ., Pişkin Ö., YÜKSEL F., Gürler O., ...More

TURKISH JOURNAL OF MEDICAL SCIENCES, vol.37, no.5, pp.267-271, 2007 (SCI-Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 37 Issue: 5
  • Publication Date: 2007
  • Journal Name: TURKISH JOURNAL OF MEDICAL SCIENCES
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Page Numbers: pp.267-271
  • Keywords: Behcet's disease, TAFI, fibrinolysis, coagulation, PROTEIN-S DEFICIENCY, FACTOR-V-LEIDEN, PROCARBOXYPEPTIDASE-U, THROMBOPHILIC FACTORS, VASCULAR INVOLVEMENT, COAGULATION, ANTIBODIES, MUTATION, TAFI
  • Dokuz Eylül University Affiliated: Yes

Abstract

Aim: The precise pathogenetic mechanisms causing thrombotic complications in Behcet's disease (BID) are still not known. To explain the pathogenesis with coagulation induction or a defective fibrinolysis superimposed on endothelial dysfunction, various hemostatic parameters were studied. Thrombin activatable fibrinolysis inhibitor (TAFI), downregulating plasmin generation and fibrinolysis, is a novel risk factor for thrombotic disorders. We studied plasma TAR levels in BD in comparison with healthy controls.